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Abstract Persistent hyperinsulinaemic hypoglycaemia of in-
fancy (PHHI), or nesidioblastosis, is a rare disorder which may 
be familial or sporadic, and which is characterized by 
unregulated secretion of insulin and profound hypoglycaemia in 
the neonate. The defect has been linked in some patients to 
mutations in the sulphonyl urea receptor gene (SUR). The 
present study investigated potential defects in the regulation of 
the insulin gene by glucose in a P-cell line (NES 2Y) derived from 
a patient with PHHI. The results show that the insulin promoter 
is unresponsive to glucose in PHHI, and that this defect can be 
attributed to impaired expression of the transcription factor 
IUF1. Because IUF1 is involved not only in linking glucose 
metabolism to the control of the insulin, but is also a major 
regulator of P-cell differentiation during embryogenesis, we 
propose that impaired expression of IUF1 contributes to P-cell 
dysfunction in PHHI by leading to abnormal P-cell differentia-
tion. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Persistent hyperinsulinaemic hypoglycaemia of infancy 
(PHHI) , or nesidioblastosis, although a rare disorder charac-
terized by unregulated secretion of insulin and profound hy-
poglycaemia in the neonatal period [1], is the most common 
cause of persistent hypoglycaemia in childhood. Newly born 
children with the disease can suffer severe brain damage if not 
diagnosed and treated immediately. Treatment in severe cases 
usually involves partial or even total pancreatectomy. 
There is controversy over the aetiology of the disease [2]. 
The term nesidioblastosis was coined in recognition of the 
histological appearance of endocrine cells lying in duct epithe-
lium with an apparent failure to aggregate into discrete islets 
of Langerhans [3]. However, severe hyperinsulinaemia can 
also occur in the presence of apparently normal islets, and 
doubt has been expressed over the concept that the condition 
is entirely due to a defect in P-cell differentiation [1]. The 
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disease occurs either in families, particularly in the Middle 
East, or sporadically. In some patients the disease has been 
mapped recently to mutat ions in the sulphonyl urea receptor 
(SUR) gene [4]. The sulphonyl urea receptor is a component 
of the KATI 5 channel that plays an important role in the mech-
anism whereby glucose metabolism in P cells is linked to in-
sulin secretion [5]. Evidence linking the disease to abnormal 
K A T P channel activity comes from the observation that cell 
lines derived from five patients with P H H I lacked such activ-
ity with a loss of glucose-insulin secretion coupling [6]. 
However, in addition to stimulating insulin secretion, glu-
cose metabolism also regulates transcription of the insulin 
gene through modulat ion of the phosphorylation state and 
D N A binding activity of the homeodomain transcription fac-
tor I U F 1 [7], which is also known as I P F 1 , I D X 1 , STF1 or 
PDX1 [8-10], and possibly other factors [11,12]. In the adult, 
expression of I U F 1 is restricted to pancreatic P cells and so-
matostat in secreting cells of the duodenum [9]. It binds to the 
consensus sequence C(T/C)TAAG located at four sites (the A 
boxes at —77, —129, —210 and —313) in the human insulin 
gene promoter [13,14]. IUF1 (PDX1) also plays an important 
role in lineage determination in the developing pancreas 
[15,16]. 
Because P H H I may be associated with P-cell hyperplasia 
during fetal development [17], and since I U F 1 is involved 
not only in linking glucose metabolism to the insulin gene 
but is also a major regulator of P-cell differentiation during 
embryogenesis, we hypothesised that defects in both these 
processes would explain some of the pathologies associated 
with P H H I . This study was undertaken to explore this hy-
pothesis in a P-cell line derived from a patient with P H H I . 
2. Materials and methods 
2.1. Cell culture 
The patient's pancreas had the appearance of diffuse nesidioblasto-
sis and islets of Langerhans were isolated by a standard method using 
collagenase digestion, and plated out in non-tissue culture Petri dishes 
(Sterilin). Seven days later the islets were transferred to T25 culture 
flasks and allowed to acquire confluency. The cells were then har-
vested with trypsin/EDTA and plated out in Sterilin dishes again. 
After 7 days the cells were replated in T25 culture flasks and the 
cell line derived by continual subculture. Cultures were monitored 
for human insulin production to help derive an active population. 
The islets were plated out into 10 cm Nunc Petri dishes using Gibco 
RPMI 1640 medium containing 11 mM glucose, supplemented with 
10% (v/v) fetal calf serum and 2 mM L-glutamine. MIN6, a P-cell line 
derived from transgenic mice expressing the SV40 large T antigen 
under the control of the rat insulin promoter [18] were grown in 
DMEM containing 5mM glucose, supplemented with 15% heat inac-
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tivated myoclone foetal calf serum (Sigma) and 2mM L-glutamine. 
MIN6 cells were used between passage 26 and 30 for all experiments. 
2.2. Plasmids 
The control construct pGL-LUC was based on the plasmid pGL2 
(Promega), with the thymidine kinase promoter (TKp) from the her-
pes simplex virus cloned 5' to the firefly luciferase gene. The construct 
pGL-LUC200 varies from this in that it contains a —50 to —250 base-
pair fragment of the human insulin gene promoter cloned upstream of 
the TKp [19]. The IUF1 cDNA [19] was cloned into the pCR3 vector 
(Invitrogen) (to generate pCR3-IUFl) by virtue of the overhanging 
A's which are the natural result of PCR amplification with Taq DNA 
polymerase (Promega). 
2.3. Transfections and luciferase assays 
Transfection conditions and luciferase assays were as previously 
described [19]. 
2.4. Electrophoretic mobility shift assays (EMSA) 
Nuclear extracts were prepared and EMSAs performed as previ-
ously described [13]. 
2.5. Western blotting 
For Western blot analysis, 5 ug samples of nuclear extract were 
fractionated by SDS-PAGE and blotted on to ECL-nitrocellulose 
membrane (Amersham) and incubated for 60 min in buffer containing 
10 mM Tris-HCl, 0.05% (v/v) Tween 20, 0.5 M NaCl, and a 1:1000 
dilution of anti-IUFl antibody [19]. The antibody-antigen complex 
was then detected by incubating the membrane for a further 60 min 
in buffer containing a 1:5000 dilution of horse-radish peroxidase-con-
jugated anti-rabbit IgG secondary antibody (ECL, Amersham). 
2.6. RT-PCR 
Total RNA was isolated following lysis of cells in 4 M guanidinium 
isothiocyanate, 0.25 M sodium citrate, 5% (wt/vol) sodium sarcosyl, 
0.2 M sodium acetate, pH 4.0. For cDNA synthesis, the RNA sample 
was heated at 65°C for 10 min, and the transcription reaction per-
formed at 37°C for 60 min in a mixture containing the following: 1 X 
reverse transcriptase reaction buffer (Promega, Southampton, UK), 
20 units RNasin (Promega), 40 pmoles driving primer, 0.25 mM 
dATP, dCTP, dTTP, and dGTP, 25 mM dithiothreitol, 0.5 ug 
RNA, and 50 units AMV reverse transcriptase (Promega). For quan-
titative RT-PCR, 10%, 5%, 2.5%, 1%, 0.1% and 0.01% of the total 
cDNA was amplified with the primers described below, using a 
35-cycle PCR with an annealing temperature of 60°C. Twenty percent 
of the PCR product was then run on an ethidium bromide-stained 1% 
agarose gel. 
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Fig. 1. Effect of glucose on insulin secretion from NES 2Y cells. 
NES 2Y cells were preincubated for 180 min in media containing 
0.5 mM glucose. The media was then replaced with that containing 
the indicated amount of glucose and media samples assayed for in-
sulin by radioimmunoassay after a further 60 min incubation. The 
data are representative of two experiments and show the mean±-
standard deviation of six separate determinations. 
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Fig. 2. Effect of glucose on pGL-LUC200 constructs in transfected 
MIN6 and NES 2Y cells. NES 2Y cells or Min6 cells were trans-
fected with pGL-LUC200 constructs. After 24 h, cells were preincu-
bated for 3 h in 0.5 mM glucose and then incubated in low 
(0.5 mM) or high (16 mM) glucose for 24 h. Values are shown as 
relative luciferase activity standardised against protein content. The 
data are representative of two separate experiments and show the 
mean ± standard deviation for four separate determinations. 
2.7. Oligonucleotides 
Oligonucleotides used in EMSAs for IUF1, IEF1 and USF have 
been described elsewhere [13,20]. The PCR primers used to quantify 
IUF1 mRNA corresponded to the mouse IPF1 sequences [8] 5'-AC-
CATGAATAGTGAGGAGCA-3' and 5'-TCACCGGGGTTCCT-
GCGGTCGCAGTGGGATCGC-3', respectively. Primers Insl and 
Ins2 used in quantification of insulin mRNA corresponded to the 
human insulin sequences 5' GCGGGCTGCGTCTAGTTGCAG-
TAG-3' and 5' ATGGCCCTGTGGATGCGCCTCCTG-3', respec-
tively, and primers USF1 and USF2, used in quantification of USF 
mRNA corresponded to USF sequences 5' ATGAAGGGGCAGCA-
GAAAACAGC-3' and 5'-TTAGTTGCTGTCATTCTTGATGAC-
3', respectively. 
2.8. Insulin measurements 
Insulin was measured by radioimmunoassay using an anti-guinea 
pig insulin antibody and 125I human insulin (Amersham). 
3. Results 
The NES2Y cells were derived from a patient (patient num-
ber 2 in [6]) who exhibited sporadic PHHI, with no parental 
consanguinity and no other affected siblings. The cell line was 
derived by continual subculture. In keeping with the charac-
teristics of insulin secretion from PHHI islets in culture [1,21], 
secretion of insulin from the NES2Y cells was unresponsive to 
glucose stimulation (Fig. 1). Glucose-stimulated insulin tran-
scription was also defective in the NES 2Y cells (Fig. 2). This 
was demonstrated by transfecting the plasmid pGL-LUC200 
which contains a —50 to —250 fragment of the human insulin 
gene promoter into NES 2Y or MIN6 cells. In MIN6 cells the 
pGL-LUC200 construct gave a five-fold increase in activity in 
16 mM glucose compared with 0.5 mM glucose. In NES 2Y 
cells there was no effect of glucose on the pGL-LUC200 con-
struct. A control vector pGL-LUC which lacked the insulin 
reporter sequences was unaffected by glucose in both cell 
types (data not shown). 
Recent studies have demonstrated that glucose activates 
306 W.M. Macfarlane et al.lFEBS Letters 413 (1997) 304-308 
insulin gene transcription by modulating the phosphorylation 
state of the transcription factor IUF1 [7,19]. IUF1 binding 
was therefore examined by EMSA in NES 2Y and MIN6 
cells. There was no detectable IUF1 binding activity in the 
NES 2Y cells (Fig. 3). Under similar conditions IUF1 binding 
activity could be detected in MIN6 cells. This was not due to 
differences in the quality of the nuclear extracts, since the 
activity of other transcription factors known to bind to the 
insulin promoter, i.e. IEF1 and USF, could be readily de-
tected in both MIN6 and NES 2Y cells (Fig. 3). IUF1 protein 
could not be detected by Western blot analysis in NES 2Y 
cells (Fig. 4). The 46 kDa form of IUF1 was present in MIN6 
cells, but as previously reported [7], it was absent from the 
non-insulin expressing cell lines oe-TC and BHK. The high 
molecular weight protein (55 kDa) seen in tracks 2 and 3 is 
always observed in (3-cell lines, but does not represent IUF1. 
The NES 2Y cells were shown by reverse transcriptase pol-
ymerase chain reaction (RT/PCR) to have slightly elevated 
M 
90 — 
69 — 
46 — 
30 — 
14 — 
7 y * 
5 H X 
S a pa 
IUF1 
Fig. 4. Western blot analysis of IUF1 in NES 2Y, MIN6, aTC and 
BHK cells. The indicated cell lines were analysed for the IUF1 pro-
tein using a specific IUF1 antibody. The arrow indicates IUF1, 
which has a molecular weight of 46 kDa. The higher molecular 
weight band in tracks 2 and 3 is observed in all (5 cells, and does 
not represent IUF1. Lane 1 contains rainbow molecular size 
markers. 
insulin mRNA levels compared to MIN6 cells, while USF 
mRNA levels were similar in both cell types (Fig. 5). How-
ever, in NES 2Y cells the IUF1 mRNA levels were more than 
10-fold less than USF mRNA, and about 103-fold less than 
insulin mRNA. In MIN6 cells IUF1 and USF mRNA levels 
were similar, both being about 102-fold less than insulin 
mRNA levels. These results confirmed that the IUF1 gene 
was expressed in NES 2Y cells but at very low levels. The 
sequence of the IUF1 cDNA synthesised from NES 2Y 
mRNA was identical to the known sequence of human 
IUF1 [19] (data not shown). 
To investigate whether the defect in glucose regulation of 
the insulin promoter in NES 2Y cells could be corrected by 
IUF1, a mammalian expression vector harbouring an IUF1 
cDNA was co-transfected into NES 2Y cells along with the 
pGL-LUC and pGL-LUC200 constructs. IUF1 had no effect 
on the control vector (data not shown). In the absence of 
IUF1 glucose had no specific effect on the pGL-LUC200 vec-
tor, but in the presence of IUF1 glucose stimulated the pGL-
LUC200 activity 5-fold (Fig. 6). Thus a full transcriptional 
response to glucose could be restored by transfecting the 
NES 2Y cells with IUF1. 
4. Discussion 
Fig. 3. EMSA analysis of transcription factor binding activity in 
NES 2Y (N) and MIN6(M) cells. NES 2Y and MIN6 cells were in-
cubated for 1 h in 16 mM glucose and analysed by EMSA for the 
binding activities of IUF1 using (oligonucleotide B [13], lanes 1 and 
2), USF (oligonucleotide USF [20] lanes 5 and 6), and IEF1 using 
oligonucleotide Jrl [20], lanes 3 and 4. 
PHHI, or nesidioblastosis, is a complex condition, mani-
fested in erratic secretion of insulin, and accompanied by a 
variety of histological appearances of the endocrine pancreas 
ranging from apparently normal islets of Langerhans, to one 
in which no recognisable islets are seen, the endocrine cells 
lying in duct epithelium. Hyperplasia of insulin cells with 
'giant' nuclei has been considered pathogenic [1-3,22]. The 
observed effects on glucose-regulated insulin secretion may 
be attributed to loss-of-function mutations in the NBF-2 re-
gion of the sulphonyl urea receptor gene (SUR) [6]. However, 
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Fig. 5. Quantitative RT-PCR of IUF1, insulin and USF mRNA levels. Comparison of quantitative PCR with primers specific for IUF1 (NES 
2Y, lanes 1-6; MIN6, lanes 7-12) insulin, and USF. Lanes 1-6 and 7-12 represent 10%, 5%, 2.5%, 1%, 0.1% and 0.01% of total cDNA as tem-
plate, respectively. M indicates kilobase size markers. The amplified IUF1 fragment has an expected size of 850 base pairs, USF 900 base pairs, 
and insulin 350 base pairs. 
these genetic defects may not account for all cases of PHHI, 
or for the full range of observed pancreatic abnormalities, and 
further candidate genes for this disorder must include those 
involved in islet cell differentiation, as well as those control-
ling insulin secretion. The present study has established that 
the insulin promoter is unresponsive to glucose in PHHI cells 
(NES 2Y) and that this can be attributed to reduced expres-
sion of the transcription factor IUF1. Overexpression of IUF1 
fully restored glucose control of the promoter in these cells. 
Recent progress has been made in understanding how glu-
cose metabolism regulates IUF1 activity in adult human islets 
and MIN6 cells. Glucose, and possibly other nutrients, acti-
vate a novel stress-activated pathway involving the MAP ki-
nase homologue, SAPK2 [23], leading to phosphorylation of 
IUF1 by an unknown IUF1 kinase [19]. Because of the low 
levels of IUF1 mRNA and undetectable levels of the protein, 
it is unlikely that the defect in the NES2Y cells is in the post-
translational modification of IUF1. Rather, the data suggest 
impaired regulation of the IUF1 gene as a result, either of a 
functional mutation within the IUF1 enhancer/promoter, or a 
defect in a transcription factor(s) controlling the gene. Little is 
known about the regulation of the IUF1 gene [24,25]. There 
is, however, evidence that IUF1 gene expression can be modu-
lated by glucose. Thus, when HIT T15 (3 cells were incubated 
in media containing elevated glucose levels for prolonged pe-
riods of time there was a concomitant decrease in IUF1 and 
insulin mRNA levels [26,27]. In the present study the de-
creased IUF1 mRNA levels were not associated with de-
creased insulin mRNA levels. 
There are no available data on the regulation of IUF1 in 
normal human fetal islets. However, the role of IUF1 in islet 
ontogeny has been studied in mice. In this species the endo-
crine pancreas originates from endodermal cells in the gut of 
embryos of about 20 somites [28,29]. All four islet cell types 
(P, oc, 8 and PP) arise from a common pluripotent precursor. 
IUF1 is expressed at the earliest stages and is essential for 
pancreatic development [30]. Co-localisation studies show 
that the endocrine cells pass through various stages where 
IUF1 is co-expressed with combinations of other hormones. 
IUF1 is subsequently extinguished in the developing fetus in 
a, 8, and PP cells, remaining co-expressed with insulin in [3 
cells in the adult [16]. It has been known for some time that 
the (3-cell hypertrophy and islet hyperplasia associated with 
PHHI are often accompanied by abnormalities in the distri-
bution and number of glucagon (a), somatostatin (8) and 
pancreatic polypeptide (PP) producing cells. This led to the 
suggestion that the histological resemblance of nesidioblas-
totic pancreata to those of immature foetuses may have arisen 
as the result of inappropriate control during the earliest 
phases of endocrine pancreatic development [17]. Further 
studies supported this conclusion, adding that in PHHI, the 
(3 cells resemble cells in the early fetal pancreas not only ana-
tomically, but by their defective recognition of nutrient secret-
agogues, and lack of glucose dependency of their c-AMP 
mediated insulin release [21]. The results of the present study 
are therefore consistent with a view that a defect in the ex-
pression of IUF1, results in aberrant development of the 
P cells in PHHI. It remains to be established how this defect 
relates to the KATP channel abnormality in this patient. PHHI 
may be a manifestation of poor nutrient sensing in the devel-
oping endocrine pancreas, raising the intriguing possibility 
that a similar defect in IUF1 expression may also contribute 
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Fig. 6. IUF1 restores glucose responsive regulation of the insulin 
promoter in transfected NES 2Y cells. NES 2Y cells were trans-
fected with pGL-LUC200, or co-transfected with pGL-LUC200 and 
pCR3-IUFl, as indicated. Cells were then incubated in 0.5 mM glu-
cose or 16 mM glucose for 24 h. Values are shown as relative lucif-
erase activity standardised against protein content. Data are repre-
sentative of two experiments and show the mean±S.D. of four 
separate determinations. 
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to the (3-cell dysfunction associated with N I D D M . The inter- [14. 
relations of fetal nutrient supply, I U F 1 expression and the 
functional development of postnatal insulin secretion is clearly 
an area demanding further study. [16 
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